Trading of Galecto was halted at 11:57 AM EST due to "LULD pause". Galecto (GLTO) Competitors $17.92 +14.21 (+383.02%) Closing price 04:00 PM EasternExtended Trading$13.19 -4.73 (-26.40%) As of 06:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLTO vs. SYBX, FNCH, PRPH, LEXX, NAII, AYTU, ABP, EDSA, THAR, and CLRBShould you be buying Galecto stock or one of its competitors? The main competitors of Galecto include Synlogic (SYBX), Finch Therapeutics Group (FNCH), ProPhase Labs (PRPH), Lexaria Bioscience (LEXX), Natural Alternatives International (NAII), Aytu BioPharma (AYTU), Abpro (ABP), Edesa Biotech (EDSA), Tharimmune (THAR), and Cellectar Biosciences (CLRB). These companies are all part of the "pharmaceutical products" industry. Galecto vs. Its Competitors Synlogic Finch Therapeutics Group ProPhase Labs Lexaria Bioscience Natural Alternatives International Aytu BioPharma Abpro Edesa Biotech Tharimmune Cellectar Biosciences Galecto (NASDAQ:GLTO) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability. Do analysts rate GLTO or SYBX? Galecto currently has a consensus target price of $10.00, indicating a potential downside of 44.20%. Given Galecto's stronger consensus rating and higher possible upside, research analysts plainly believe Galecto is more favorable than Synlogic.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galecto 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has more risk & volatility, GLTO or SYBX? Galecto has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Comparatively, Synlogic has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Is GLTO or SYBX more profitable? Synlogic's return on equity of -8.09% beat Galecto's return on equity.Company Net Margins Return on Equity Return on Assets GalectoN/A -115.70% -95.42% Synlogic N/A -8.09%-5.50% Which has stronger earnings & valuation, GLTO or SYBX? Synlogic is trading at a lower price-to-earnings ratio than Galecto, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalectoN/AN/A-$21.44M-$13.13-1.36SynlogicN/AN/A-$23.36M-$0.08-21.19 Does the media refer more to GLTO or SYBX? In the previous week, Galecto had 10 more articles in the media than Synlogic. MarketBeat recorded 10 mentions for Galecto and 0 mentions for Synlogic. Galecto's average media sentiment score of 0.02 beat Synlogic's score of 0.00 indicating that Galecto is being referred to more favorably in the media. Company Overall Sentiment Galecto Neutral Synlogic Neutral Do institutionals & insiders hold more shares of GLTO or SYBX? 14.2% of Galecto shares are held by institutional investors. Comparatively, 63.4% of Synlogic shares are held by institutional investors. 10.8% of Galecto shares are held by insiders. Comparatively, 3.0% of Synlogic shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryGalecto beats Synlogic on 9 of the 13 factors compared between the two stocks. Get Galecto News Delivered to You Automatically Sign up to receive the latest news and ratings for GLTO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GLTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLTO vs. The Competition Export to ExcelMetricGalectoMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.74M$3.32B$6.10B$10.53BDividend YieldN/A2.29%5.51%4.67%P/E Ratio-1.3621.5485.6826.86Price / SalesN/A422.92582.47185.05Price / CashN/A46.3226.3031.10Price / Book1.6310.0613.246.72Net Income-$21.44M-$52.22M$3.30B$276.35M7 Day Performance381.72%5.85%4.67%3.10%1 Month Performance502.35%12.06%8.40%10.19%1 Year Performance111.70%26.14%88.01%40.34% Galecto Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLTOGalecto0.6817 of 5 stars$17.92+383.0%$10.00-44.2%-68.2%$23.74MN/A-1.3640Trending NewsGap UpTrading HaltedHigh Trading VolumeSYBXSynlogicN/A$1.65-2.9%N/A+11.6%$19.32M$10K-20.6480Positive NewsGap DownFNCHFinch Therapeutics Group0.8021 of 5 stars$12.00-2.0%N/A+3.8%$19.27MN/A-1.36190News CoveragePRPHProPhase Labs0.4397 of 5 stars$0.45+3.5%N/A-75.8%$18.82M$5.59M-0.36130Gap UpLEXXLexaria Bioscience2.601 of 5 stars$0.91-7.1%$4.00+338.1%-73.7%$17.86M$460K-1.367NAIINatural Alternatives International1.2787 of 5 stars$2.89-0.7%N/A-40.9%$17.86M$125.48M-1.27290Gap UpAYTUAytu BioPharma3.3621 of 5 stars$1.79+4.7%$9.17+412.1%-6.8%$17.74M$66.38M-0.63160Gap UpABPAbpro2.7833 of 5 stars$0.22-14.4%$4.00+1,719.0%N/A$17.63M$183K0.0015EDSAEdesa Biotech2.581 of 5 stars$2.46+0.4%$5.00+103.3%-32.4%$17.32MN/A-1.8620THARTharimmune2.7559 of 5 stars$2.90-0.2%$17.00+487.2%+40.9%$17.08MN/A-0.472News CoverageGap DownCLRBCellectar Biosciences2.4936 of 5 stars$5.33-1.6%$375.00+6,940.9%-90.7%$17.01MN/A-0.2710News CoverageGap Down Related Companies and Tools Related Companies Synlogic Competitors Finch Therapeutics Group Competitors ProPhase Labs Competitors Lexaria Bioscience Competitors Natural Alternatives International Competitors Aytu BioPharma Competitors Abpro Competitors Edesa Biotech Competitors Tharimmune Competitors Cellectar Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLTO) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galecto, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galecto With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
